Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
NCT ID: NCT07011511
Last Updated: 2025-07-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
72 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-06-30
Study Completion Date
2027-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of MMV055 administered alone (Part A) and in combination with MMV371 (Part B) in healthy participants.
It is planned to enroll up to 6 sequential cohorts of 8 healthy male participants and healthy female participants of non-childbearing potential in Part A. In Part B, up to 3 sequential cohorts of 8 healthy male participants and healthy non-pregnant, non-lactating female participants will be enrolled. In each cohort, participants will be randomised in a ratio of 6 active investigational medicinal product (IMP) to 2 placebo.
Part A of the study will include two components, Parts A1 and A2. Part A1 includes two initial cohorts, with planned doses of 40 and 100mg, respectively. It is intended to document the human elimination T1/2 of MMV055, which will then be used to shorten the proposed End of Study (EOS) of 48 weeks, if possible.
All cohorts will follow a sentinel dosing design. On Day 1, two sentinel participants (sentinel group) will be randomly assigned to receive a single IM dose of either active IMP or placebo (1 participant each) to assess safety and tolerability (including ISRs).
The sentinel group will be dosed concomitantly at least 7 days prior to the rest of the cohort (main group). The main group will comprise 6 participants randomly assigned to receive a single IM dose of either active IMP or placebo in a 5:1 ratio to assess safety and tolerability (including ISRs).
It is planned to enroll up to 6 sequential cohorts of 8 healthy male participants and healthy female participants of non-childbearing potential in Part A. In Part B, up to 3 sequential cohorts of 8 healthy male participants and healthy non-pregnant, non-lactating female participants will be enrolled. In each cohort, participants will be randomised in a ratio of 6 active investigational medicinal product (IMP) to 2 placebo.
Part A of the study will include two components, Parts A1 and A2. Part A1 includes two initial cohorts, with planned doses of 40 and 100mg, respectively. It is intended to document the human elimination T1/2 of MMV055, which will then be used to shorten the proposed End of Study (EOS) of 48 weeks, if possible.
All cohorts will follow a sentinel dosing design. On Day 1, two sentinel participants (sentinel group) will be randomly assigned to receive a single IM dose of either active IMP or placebo (1 participant each) to assess safety and tolerability (including ISRs).
The sentinel group will be dosed concomitantly at least 7 days prior to the rest of the cohort (main group). The main group will comprise 6 participants randomly assigned to receive a single IM dose of either active IMP or placebo in a 5:1 ratio to assess safety and tolerability (including ISRs).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants
NCT06558643
Malaria,Falciparum
COMPLETED
PHASE1
MMV533 Plasmodium Falciparum Volunteer Infection Study
NCT05205941
Malaria
COMPLETED
PHASE1
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
NCT04323306
Malaria
COMPLETED
PHASE1
Experimental Vaccine for Plasmodium Falciparum Malaria
NCT00340431
Plasmodium Falciparum Malaria
Vaccines
COMPLETED
PHASE1
Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults
NCT05891236
Malaria
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Malaria, Falciparum
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
PREVENTION
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A1 Regimen A
Group Type
EXPERIMENTAL
MMV055 Dose 1
Intervention Type
DRUG
40mg
Matching placebo Part A
Intervention Type
DRUG
Part A
Part A1 Regimen B
Group Type
EXPERIMENTAL
MMV055 Dose 2
Intervention Type
DRUG
100mg
Matching placebo Part A
Intervention Type
DRUG
Part A
Part A2 Regimen C
Group Type
EXPERIMENTAL
MMV055 Dose 3
Intervention Type
DRUG
200mg
Matching placebo Part A
Intervention Type
DRUG
Part A
Part A2 Regimen D
Group Type
EXPERIMENTAL
MMV055 Dose 4
Intervention Type
DRUG
400mg
Matching placebo Part A
Intervention Type
DRUG
Part A
Part A2 Regimen E
Group Type
EXPERIMENTAL
MMV055 Dose 5
Intervention Type
DRUG
800mg
Matching placebo Part A
Intervention Type
DRUG
Part A
Part A2 Regimen F
Group Type
EXPERIMENTAL
MMV055 Dose 6
Intervention Type
DRUG
TBCmg
Matching placebo Part A
Intervention Type
DRUG
Part A
Part B Combination 1
Group Type
EXPERIMENTAL
Matching placebo Part B
Intervention Type
DRUG
Part B
MMV055/MMV371 Combo 1
Intervention Type
COMBINATION_PRODUCT
Combination 1
Part B Combination 2
Group Type
EXPERIMENTAL
Matching placebo Part B
Intervention Type
DRUG
Part B
MMV055/MM371 Combo 2
Intervention Type
COMBINATION_PRODUCT
Combination 2
Part B Combination 3
Group Type
EXPERIMENTAL
Matching placebo Part B
Intervention Type
DRUG
Part B
MMV055/MMV371 Combo 3
Intervention Type
COMBINATION_PRODUCT
Combination 3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MMV055 Dose 1
40mg
Intervention Type
DRUG
MMV055 Dose 2
100mg
Intervention Type
DRUG
MMV055 Dose 3
200mg
Intervention Type
DRUG
MMV055 Dose 4
400mg
Intervention Type
DRUG
MMV055 Dose 5
800mg
Intervention Type
DRUG
MMV055 Dose 6
TBCmg
Intervention Type
DRUG
Matching placebo Part A
Part A
Intervention Type
DRUG
Matching placebo Part B
Part B
Intervention Type
DRUG
MMV055/MMV371 Combo 1
Combination 1
Intervention Type
COMBINATION_PRODUCT
MMV055/MM371 Combo 2
Combination 2
Intervention Type
COMBINATION_PRODUCT
MMV055/MMV371 Combo 3
Combination 3
Intervention Type
COMBINATION_PRODUCT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Must provide written informed consent
2. Must be willing and able to communicate and participate in the whole study
3. Aged 18 to 60 years inclusive at the time of signing informed consent
4. Must agree to adhere to the contraception requirements defined in the study protocol
5. Healthy male or healthy WONCBP (Parts A and B), or healthy non-pregnant, non-lactating female participants (Part B only) according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead ECG, and laboratory safety tests without any clinically significant abnormalities. Safety bloods, urinalysis, ECGs and vital signs to be re-checked at admission and/or pre-dose
6. Body mass index (BMI) of 19.0 to 30.0 kg/m2 as measured at screening
7. Weight ≥50 kg for males and ≥45 kg for females at screening
2. Must be willing and able to communicate and participate in the whole study
3. Aged 18 to 60 years inclusive at the time of signing informed consent
4. Must agree to adhere to the contraception requirements defined in the study protocol
5. Healthy male or healthy WONCBP (Parts A and B), or healthy non-pregnant, non-lactating female participants (Part B only) according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead ECG, and laboratory safety tests without any clinically significant abnormalities. Safety bloods, urinalysis, ECGs and vital signs to be re-checked at admission and/or pre-dose
6. Body mass index (BMI) of 19.0 to 30.0 kg/m2 as measured at screening
7. Weight ≥50 kg for males and ≥45 kg for females at screening
Exclusion Criteria
1. Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients (Parts A and B), Wellvone®/Mepron® and/or Malarone® (Part B only)
2. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
3. History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator
4. Family history of sudden death, or family history of clinically significant cardiovascular disease, as judged by the investigator
5. Systolic BP \>140 or \<90 mmHg, diastolic BP \>90 or \<50 mmHg, or heart rate (HR) (based on vital signs assessment) \>100 or \<45 bpm, confirmed by repeat assessment at screening
6. Any finding in the medical examination (including BP, HR or ECG) deviating from normal and assessed as clinically relevant by the investigator
7. History or presence of known structural cardiac abnormalities, family history of long QT syndrome, cardiac syncope or recurrent, idiopathic syncope, exercise related clinically significant cardiac events. Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG or clinically important abnormalities that may interfere with the interpretation of QT changes
8. Presence of sinus node dysfunction, clinically significant PR interval prolongation (\>220 msec), intermittent second- or third-degree atrioventricular block, complete bundle branch block, sustained cardiac arrhythmias including (but not limited to) atrial fibrillation or supraventricular tachycardia; any symptomatic arrhythmia with the exception of isolated extra systoles, abnormal T wave morphology which may impact on the QT/QTc assessment, or QTcF \>450 msec based on the mean of the triplicate values and confirmed by single repeat assessment at screening
9. Participants with a history of cholecystectomy or gall stones
10. Participants who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
11. Participants with tattoos or scars or other significant dermatological conditions overlying the deltoid or gluteal region which may interfere with injection site assessments, as determined by the investigator or delegate at screening
12. Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis as judged by the investigator (laboratory parameters are listed in the study protocol). Participants with Gilbert's Syndrome are not allowed
13. Dyslipidaemia (cholesterol and/or triglycerides) requiring pharmacological intervention or fasting triglycerides \>2.26 mmol/L, fasting cholesterol \>6.20 mmol/L, low density lipoprotein cholesterol \>3.75 mmol/L)
14. Fasting blood glucose ≥6.1 mmol/L
15. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results
16. Transaminases (ALT or AST) \>ULN
17. Females who are pregnant or lactating (all female participants must have a negative highly sensitive serum pregnancy test at screening and a negative urine pregnancy test at admission)
18. Part A only: females of childbearing potential. A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or is post-menopausal (had no menses for 12 months without an alternative medical cause and a serum follicle stimulating hormone \[FSH\] concentration ≥40 IU/L).
19. Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
20. Participants who have previously been administered MMV055 in this study
21. Participants who report to have previously received MMV371
22. Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
23. Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day, up to 800 mg ibuprofen per day, hormonal contraception or HRT) in the 14 days before IMP administration (see study protocol). Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the washout is such that no pharmacodynamic activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardise the safety of the trial participant; and if the use of medication is not considered to interfere with the objectives of the study.
24. Participants who are taking, or who have taken, rifampin/rifabutin, tetracycline and indinavir in the 30 days before IMP administration (Part B only)
25. Live vaccines within 30 days of IMP administration, or plans to receive such vaccines during the study
26. Participants who have had a COVID 19 vaccine within 14 days before dosing
27. History of any drug or alcohol abuse in the past 2 years
28. Regular alcohol consumption in males \>21 units per week and in females \>14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
29. A confirmed positive alcohol breath test at screening or admission
30. Current smokers and those who have smoked within the last 12 months
31. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
32. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
33. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in the study protocol) at screening or admission
34. Male participants with pregnant or lactating partners
35. A score of SI 4 to 5 (related to suicidal ideation) or any SB score (related to suicidal behaviour) as assessed using the Columbia-Suicide Severity Rating Scale (C SSRS)
36. Participants who are, or are immediate family members of, a study site or sponsor employee
37. Failure to satisfy the investigator of fitness to participate for any other reason
2. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
3. History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator
4. Family history of sudden death, or family history of clinically significant cardiovascular disease, as judged by the investigator
5. Systolic BP \>140 or \<90 mmHg, diastolic BP \>90 or \<50 mmHg, or heart rate (HR) (based on vital signs assessment) \>100 or \<45 bpm, confirmed by repeat assessment at screening
6. Any finding in the medical examination (including BP, HR or ECG) deviating from normal and assessed as clinically relevant by the investigator
7. History or presence of known structural cardiac abnormalities, family history of long QT syndrome, cardiac syncope or recurrent, idiopathic syncope, exercise related clinically significant cardiac events. Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG or clinically important abnormalities that may interfere with the interpretation of QT changes
8. Presence of sinus node dysfunction, clinically significant PR interval prolongation (\>220 msec), intermittent second- or third-degree atrioventricular block, complete bundle branch block, sustained cardiac arrhythmias including (but not limited to) atrial fibrillation or supraventricular tachycardia; any symptomatic arrhythmia with the exception of isolated extra systoles, abnormal T wave morphology which may impact on the QT/QTc assessment, or QTcF \>450 msec based on the mean of the triplicate values and confirmed by single repeat assessment at screening
9. Participants with a history of cholecystectomy or gall stones
10. Participants who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
11. Participants with tattoos or scars or other significant dermatological conditions overlying the deltoid or gluteal region which may interfere with injection site assessments, as determined by the investigator or delegate at screening
12. Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis as judged by the investigator (laboratory parameters are listed in the study protocol). Participants with Gilbert's Syndrome are not allowed
13. Dyslipidaemia (cholesterol and/or triglycerides) requiring pharmacological intervention or fasting triglycerides \>2.26 mmol/L, fasting cholesterol \>6.20 mmol/L, low density lipoprotein cholesterol \>3.75 mmol/L)
14. Fasting blood glucose ≥6.1 mmol/L
15. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results
16. Transaminases (ALT or AST) \>ULN
17. Females who are pregnant or lactating (all female participants must have a negative highly sensitive serum pregnancy test at screening and a negative urine pregnancy test at admission)
18. Part A only: females of childbearing potential. A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or is post-menopausal (had no menses for 12 months without an alternative medical cause and a serum follicle stimulating hormone \[FSH\] concentration ≥40 IU/L).
19. Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
20. Participants who have previously been administered MMV055 in this study
21. Participants who report to have previously received MMV371
22. Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
23. Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day, up to 800 mg ibuprofen per day, hormonal contraception or HRT) in the 14 days before IMP administration (see study protocol). Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the washout is such that no pharmacodynamic activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardise the safety of the trial participant; and if the use of medication is not considered to interfere with the objectives of the study.
24. Participants who are taking, or who have taken, rifampin/rifabutin, tetracycline and indinavir in the 30 days before IMP administration (Part B only)
25. Live vaccines within 30 days of IMP administration, or plans to receive such vaccines during the study
26. Participants who have had a COVID 19 vaccine within 14 days before dosing
27. History of any drug or alcohol abuse in the past 2 years
28. Regular alcohol consumption in males \>21 units per week and in females \>14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
29. A confirmed positive alcohol breath test at screening or admission
30. Current smokers and those who have smoked within the last 12 months
31. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
32. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
33. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in the study protocol) at screening or admission
34. Male participants with pregnant or lactating partners
35. A score of SI 4 to 5 (related to suicidal ideation) or any SB score (related to suicidal behaviour) as assessed using the Columbia-Suicide Severity Rating Scale (C SSRS)
36. Participants who are, or are immediate family members of, a study site or sponsor employee
37. Failure to satisfy the investigator of fitness to participate for any other reason
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Quotient Sciences
INDUSTRY
Sponsor Role
collaborator
The Doctors Laboratory Ltd
INDUSTRY
Sponsor Role
collaborator
Medicines for Malaria Venture
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Quotient Sciences
Nottingham, United Kingdom, United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
https://www.quotientsciences.com/volunteers
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMV_MMV055_24_01_FIH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model
NCT01397227
COMPLETED
PHASE1/PHASE2
Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults
NCT05913973
COMPLETED
PHASE1
A Study to Compare Two Dosing Regimens for a New Malaria Vaccine
NCT06141057
ACTIVE_NOT_RECRUITING
PHASE1
A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria
NCT00811356
TERMINATED
PHASE1
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
NCT07235020
COMPLETED
PHASE2
Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
NCT01524341
COMPLETED
PHASE2
A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria
NCT02044198
COMPLETED
PHASE1/PHASE2
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
NCT01157897
COMPLETED
PHASE1/PHASE2
To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers
NCT03867331
COMPLETED
PHASE1
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
NCT05911828
RECRUITING
PHASE1
Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
NCT02174978
COMPLETED
PHASE1
MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine
NCT05197751
UNKNOWN
PHASE1
Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F
NCT04238689
COMPLETED
PHASE1
MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria
NCT02880241
TERMINATED
PHASE2
Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
NCT01081847
COMPLETED
PHASE1
Dose Finding Trial of R21/Matrix-M in School Children
NCT07074665
NOT_YET_RECRUITING
PHASE2
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
NCT01753323
COMPLETED
PHASE2
Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects
NCT00675064
COMPLETED
PHASE1
A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults
NCT04296279
UNKNOWN
PHASE1
A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults
NCT00385047
COMPLETED
PHASE1/PHASE2
Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine
NCT00509158
COMPLETED
PHASE1/PHASE2
Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
NCT04709692
COMPLETED
PHASE2
A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate
NCT07124156
NOT_YET_RECRUITING
PHASE1
Trial to Assess the Efficacy of Malaria Vaccine PfCS 102
NCT01031524
COMPLETED
PHASE1/PHASE2
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
NCT00312702
COMPLETED
PHASE1/PHASE2